ABCA1 | ATP-binding cassette, sub-family A (ABC1), member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ANXA1 | Annexin A1 | Cancer-related genes FDA approved drug targets Plasma proteins Transporters
| | | | | Expressed in all |
ATP1A1 | ATPase, Na+/K+ transporting, alpha 1 polypeptide | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CACNA2D2 | Calcium channel, voltage-dependent, alpha 2/delta subunit 2 | FDA approved drug targets Transporters
| | | | | Tissue enriched |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GLRA2 | Glycine receptor, alpha 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
HMGCR | 3-hydroxy-3-methylglutaryl-CoA reductase | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
RYR1 | Ryanodine receptor 1 (skeletal) | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A1 | Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A3 | Solute carrier family 12 (sodium/chloride transporter), member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC22A8 | Solute carrier family 22 (organic anion transporter), member 8 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC5A2 | Solute carrier family 5 (sodium/glucose cotransporter), member 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC6A1 | Solute carrier family 6 (neurotransmitter transporter), member 1 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC8A1 | Solute carrier family 8 (sodium/calcium exchanger), member 1 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
SNAP25 | Synaptosomal-associated protein, 25kDa | FDA approved drug targets Transporters
| | | | | Tissue enriched |
UGCG | UDP-glucose ceramide glucosyltransferase | Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |